Email this article Taxoter as a new standard for treatment of hormone-refractory prostate cancer
- Authors: Rusakov I.G.1, Alekseyev B.Y.1, Vereshagina G.V.1, Gritskevich A.A.1
-
Affiliations:
- P.A. Gertzen Moscow Research Institute of Oncology
- Issue: Vol 4, No 4 (2008)
- Pages: 49-52
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER
- Published: 30.12.2008
- URL: https://oncourology.abvpress.ru/oncur/article/view/1036
- DOI: https://doi.org/10.17650/1726-9776-2008-4-4-49-52
- ID: 1036
Cite item
Full Text
Abstract
One of the options in the treatment of hormone-refractory prostate cancer is the administration of cytostatic agents. This article addresses the Taxoter — one of the cytostatic agents. Clinical studies discussed in the article have demonstrated the high activity and efficacy of the agent which allows using it in the treatment of hormone-refractory prostate cancer.
About the authors
I. G. Rusakov
P.A. Gertzen Moscow Research Institute of Oncology
Author for correspondence.
Russian Federation
B. Ya. Alekseyev
P.A. Gertzen Moscow Research Institute of OncologyRussian Federation
G. V. Vereshagina
P.A. Gertzen Moscow Research Institute of OncologyRussian Federation
A. A. Gritskevich
P.A. Gertzen Moscow Research Institute of OncologyRussian Federation
References
Supplementary files
